Latest Ratios: P/E Ratio -9999.0x · EV/EBITDA 29.8x · ROE -29.1%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.0B | $4.0B | $5.9B | $10.6B | $7.9B | $6.6B | $3.3B | — | — | — |
| Enterprise Value | $2.5B | $3.5B | $6.0B | $9.6B | $7.4B | $6.0B | $2.9B | — | — | — |
| P/E Ratio → | -9999.00 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.21 | 3.89 | 9.49 | 37.16 | 67.86 | 95.39 | 44.36 | — | — | — |
| P/B Ratio | 2.99 | 4.00 | 5.72 | 8.47 | 10.67 | 8.57 | 5.57 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.42 | 9.59 | 33.83 | 63.57 | 87.16 | 38.33 | — | — | — |
| EV / EBITDA | 29.84 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.4% |
| Operating Margin | -13.3% | -13.3% | -48.3% | -154.1% | -389.4% | -570.0% | — | -214.4% | -3.1% | 58.4% |
| Net Profit Margin | -28.8% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -164.4% | -5.7% | 39.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.1% | -29.1% | -15.4% | -51.9% | -59.1% | -59.2% | -112.2% | — | -26.7% | 77.0% |
| ROA | -17.4% | -17.4% | -10.1% | -32.6% | -36.4% | -43.8% | -52.8% | -28.3% | -0.8% | 3.9% |
| ROIC | -12.7% | -12.7% | -32.3% | -120.9% | -154.3% | -170.4% | — | — | — | 100.2% |
| ROCE | -11.0% | -11.0% | -20.1% | -33.0% | -47.4% | -52.4% | — | -61.7% | -0.7% | 7.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.34 | 0.26 | 0.38 | 0.16 | 0.01 | — | 0.50 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 28.97 | 0.02 |
| Net Debt / Equity | — | -0.49 | 0.06 | -0.76 | -0.67 | -0.74 | -0.76 | — | -23.80 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -1381.54 | -0.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | -0.72 | — |
| Interest Coverage | -12.21 | -12.21 | -6.32 | -22.87 | -40.29 | -451.44 | -73.20 | -594.23 | -18.71 | — |
Net cash position: cash ($902M) exceeds total debt ($414M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 5.14 | 1.62 | 2.05 | 4.43 |
| Quick Ratio | 1.91 | 1.91 | 4.54 | 6.83 | 3.66 | 4.14 | 5.12 | 1.61 | 2.05 | 4.43 |
| Cash Ratio | 1.49 | 1.49 | 4.04 | 6.05 | 3.44 | 3.85 | 4.38 | 1.25 | 1.36 | 0.04 |
| Asset Turnover | — | 0.59 | 0.38 | 0.15 | 0.09 | 0.06 | 0.10 | 0.21 | 0.11 | 0.10 |
| Inventory Turnover | 12.75 | 12.75 | 9.81 | 7.42 | 6.31 | — | — | — | — | -8.73 |
| Days Sales Outstanding | — | 88.79 | 72.67 | 201.05 | 138.87 | 310.49 | 402.06 | 211.19 | 806.53 | 3538.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $184M | $183M | $176M | $159M | $141M | $118M | $132M | $100M | $132M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LEGN stock.
Legend Biotech Corporation's current P/E ratio is -9999.0x. This places it at the 50th percentile of its historical range.
Legend Biotech Corporation's current EV/EBITDA is 29.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Legend Biotech Corporation's return on equity (ROE) is -29.1%. The historical average is -34.6%.
Based on historical data, Legend Biotech Corporation is trading at a P/E of -9999.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Legend Biotech Corporation has 60.3% gross margin and -13.3% operating margin.
Key Metrics
Top Statement Risk
Operating cash conversion lagging earnings
Premium Multiples Price in Carvykti Scale
Based on reported figures, LEGN trades at 2.38 times sales and 32.58 times trailing EV/EBITDA, a premium that implies the market expects Carvykti revenue to compound well beyond current levels before the equity justifies the price.
The reported trailing P/E of -9999 is not meaningful because earnings are distorted by sporadic net income swings, so EV/EBITDA and P/S are the more usable anchors. A 32.58 times EV/EBITDA multiple, compared with mature large-cap pharma ranges, suggests investors are capitalizing future operating leverage rather than current cash generation. The forward EV/EBITDA of 29.79 implies only modest expected EBITDA improvement, which warrants monitoring given that the market is paying for growth the operating line has not yet demonstrated consistently.
Gross Margin Erosion Versus Operating Recovery
According to reported income statements, gross margin slid from 73.0% in 2024Q2 to 58.9% in 2026Q3, while operating margin swung from -43.7% to 13.0%, so the operating improvement appears to come from cost control rather than pricing or unit economics.
The gross margin decline may reflect rising per-patient manufacturing and logistics costs as volumes scale, a pattern consistent with individualized autologous production. Operating margin turning positive at 13.0% in the latest quarter is a meaningful inflection, yet it sits against a net margin of 14.4% that is not reconciled with negative operating cash flow. Investors should treat the operating recovery as early evidence that requires confirmation over several more quarters.
Returns Turning Positive From Deep Losses
Based on reported ratios, ROIC moved from -5.3% in 2024Q4 to 3.9% in 2026Q3 and ROE to 4.1%, a reversal that is directionally encouraging but still low relative to a roughly 1.3 billion dollar equity base.
The shift from negative to positive returns appears driven primarily by margin improvement rather than asset efficiency, since asset turnover of 0.21 remains very low for a commercial biotech. Returns of roughly 4% sit well below the cost of capital typically applied to this risk profile, suggesting the business has not yet created economic value on the capital deployed. Sustained ROIC above the cost of capital would be the clearer signal of compounding.
Deleveraging Shrinks Refinancing Exposure
As reported in financial statements, total debt fell from 389.3 million dollars in 2026Q1 to 167.4 million dollars in 2026Q3, lowering debt-to-equity from 0.40 to 0.13 and easing refinancing pressure considerably.
Interest coverage of 13.67 in the latest quarter, after a distorted 288.50 in the prior quarter, indicates that debt service is comfortable on current earnings, though the coverage series is too volatile to rely on heavily. The debt reduction appears to have been funded in part from cash accumulation, which suggests management prioritized balance sheet flexibility. Investors should monitor whether debt repayment continues without drawing down the cash reserve needed for operating burn.
Cash Cushion Covers Burn Under Stress
Based on reported figures, the current ratio of 3.95 and quick ratio of 3.82 in 2026Q3, backed by 460.7 million dollars of cash, provide a substantial buffer against near-term operating shocks, though the cushion has narrowed from 5.20 in 2025Q1.
Because the quick ratio is nearly identical to the current ratio, inventory dependence is low, which reduces the risk of a liquidity squeeze from unsold product. The declining current ratio trend suggests the liquidity buffer is being consumed gradually as operations are funded. Under a severe stress scenario, the reported cash balance covers many quarters of current negative operating cash flow, but that runway shortens quickly if working capital swings reverse.
Net Margin Overstates Cash Earning Power
According to reported quarterly figures, LEGN's 14.4% net margin in 2026Q3 coexists with an FCF margin of -11.5%, a gap that may make headline profitability a misleading gauge of the business's true earning power.
The most commonly misapplied ratio for a company like this is net margin, because collaboration accounting with Janssen and non-operating items can produce net income well above underlying cash generation. Free cash flow margin and operating cash flow relative to revenue are better anchors, since they capture the working capital and manufacturing cash demands that the income statement can defer. Investors should monitor whether net margin and FCF margin converge over the next several reporting periods.